4 results
The main objective of this study is to investigate gender differences in P-gp function at the blood brain barrier, in order to gain further insight into the impact of these differences on the action of pharmaceuticals (antidepressants and…
Primary objectivesTo compare overall survival for MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A to atezolizumab in combination with the background therapy of etoposide/platinum followed by…
Primary objectiveEvaluation of [18F]MC225 to measure the P-glycoprotein function in Alzheimer*s disease, Mild Cognitive Impairment and Parkinson*s disease. Secondary objectives1. Evaluation of blood-brain barrier integrity using [18F]MC225 and MRI…
1) Objective: To evaluate the safety and tolerability of the pembrolizumab combination therapy.2) Objective: To estimate PSA response rate of the pembrolizumab combination therapy. PSA response is defined as a reduction in the PSA level of 50% or…